Login to Your Account



Other News To Note


Thursday, December 13, 2012

• Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, submitted a marketing authorization application to the European Medicines Agency for Alpharadin (radium-223 dichloride) for the treatment of castration-resistant prostate cancer patients with bone metastases. The submission triggers a €50 million (US$65.7 million) milestone payment under the firms' 2009 agreement, and it is based on positive data from the Phase III ALSYMPCA study, in which Alpharadin significantly increased overall survival by 44 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription